Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) stock closed at $268.61 on 8/1/24 after a major increase of 13.1%. Moreover, this advance was accompanied by unusually high trading volume at 196% of normal. The stock has been strong relative to the market over the last nine months and has risen 13.6% during the last week.
Current PriceTarget Research Rating
With future capital returns forecasted to be below the cost of capital, ALNY is expected to be a major Value Eraser.
Alnylam Pharmaceuticals is currently unrated.
Rating Review
The stock is currently unrated.
Be the first to comment